CT and MRI scans of the neck, chest, abdomen, and pelvis were performed as previously described [13 (link)]. All 22 patients underwent 68Ga-DOTATATE and 18F-FDG PET/CT, and CT/MRI. In addition, 12 patients also underwent 18F-FDOPA PET/CT and 11 underwent 18F-FDA PET/CT. All imaging studies were performed within a median of 8.5 days.
PET/CT scans from the upper thighs to the skull were performed 60 min, 60 min, 30 min, and approximately 8 min after intravenous injection of 68Ga-DOTATATE, 18F-FDG, 18F-FDOPA, and 18F-FDA at mean administered activities of 191.4±8.3 MBq, 316.5±59.4 MBq, 466.3±13.0 MBq, and 39.3 ± 0.7 MBq, respectively. Carbidopa (200 mg) was administered orally 60 min before each 18F-FDOPA scan [23 (link)]. All PET/CT scans were performed on a Siemens Biograph-mCT 64 scanner and a Biograph-mCT 128 PET/CT scanner (Siemens Medical Solutions). PET images were reconstructed using an iterative algorithm provided by the manufacturer, also utilizing point spread function and time of flight. Low-dose CT scans for attenuation correction and anatomical coregistration were performed without administration of contrast agent and were used for anatomical localization.
PET/CT scans from the upper thighs to the skull were performed 60 min, 60 min, 30 min, and approximately 8 min after intravenous injection of 68Ga-DOTATATE, 18F-FDG, 18F-FDOPA, and 18F-FDA at mean administered activities of 191.4±8.3 MBq, 316.5±59.4 MBq, 466.3±13.0 MBq, and 39.3 ± 0.7 MBq, respectively. Carbidopa (200 mg) was administered orally 60 min before each 18F-FDOPA scan [23 (link)]. All PET/CT scans were performed on a Siemens Biograph-mCT 64 scanner and a Biograph-mCT 128 PET/CT scanner (Siemens Medical Solutions). PET images were reconstructed using an iterative algorithm provided by the manufacturer, also utilizing point spread function and time of flight. Low-dose CT scans for attenuation correction and anatomical coregistration were performed without administration of contrast agent and were used for anatomical localization.
